Speyside supported a pharmaceutical company in advancing cancer policies in Brazil and facilitating the inclusion of an innovative metastatic melanoma treatment in the public health system (SUS). The work involved regulatory and stakeholder analysis, engagement with decision-makers during CONITEC’s technology incorporation process, and continuous monitoring amid COVID-19 disruptions. These efforts positioned the product as one of the top two treatment options within CONITEC and provided the company with critical insights and ministry connections to support the incorporation process.

A renowned pharmaceutical company reached out to Speyside looking for support to enhance cancer policies in Brazil and to incorporate its most innovative cancer treatment for metastatic melanoma patients in the Brazilian Public Health System (SUS).

In depth analysis of current regulation, bills, laws and relevant stakeholders.

Engagement with key stakeholders involved with cancer policies and HTA in Brazil

Engagement with decision makers during the National Commission for the Incorporation of Technologies analysis

Monitoring and strategic reports about the company, healthcare sector and cancer policies in Brazil

Speyside helped position the company’s product as one of the top two alternatives for treating Metastatic Melanoma within CONITEC.

Speyside anticipated meetings alterations, new agendas and other changes that were constantly happening in CONITEC amid the COVID-19 pandemic.

Finally, Speyside was able to provide insights and proper contact within the Ministry: a key resource for any incorporation flow.